Minigastrin

Minigastrin (also mini gastrin) is a form of gastrin. Its sequence is H-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2.
Minigastrin has shown to be a potential therapeutic agent for thyroid carcinoma by targeting cancer-promoting cholecystokinin receptors.
A 2018 study further elaborates by using radiochemical labeling to show that Indium-111 labeled minigastrin peptides showing to have stronger affinity to cholecystokinin B receptors (CCK2) in neuroendocrine cancers.